Pellegrino Marcella, D'Oria Luisa, De Luca Carmen, Chiaradia Giacomina, Licameli Angelo, Neri Caterina, Nucci Marta, Visconti Daniela, Caruso Alessandro, De Santis Marco
Teratology Information Service, Department of Obstetrics and Gynecology, Fetal Diagnosis and Therapy Unit, Catholic University of Sacred Heart, Policlinico A. Gemelli Hospital, Rome, Italy.
Department of Statistics, Catholic University of Sacred Heart, Policlinico A. Gemelli Hospital, Rome, Italy.
Curr Drug Saf. 2018;13(1):3-11. doi: 10.2174/1574886312666171030125804.
There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications.
Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women.
Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes.
Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.
单独局部使用噻吗洛尔或噻吗洛尔与其他抗青光眼药物联合使用后，关于妊娠及胎儿/新生儿结局存在诸多矛盾之处。
通过电话访谈对75名暴露于抗青光眼药物的孕妇进行前瞻性随访。27名女性单独使用噻吗洛尔进行治疗，48名女性将噻吗洛尔作为多药联合治疗的一部分。我们选取了187名健康孕妇作为对照组。
单独局部使用噻吗洛尔或噻吗洛尔与其他抗青光眼药物联合使用并不影响妊娠或胎儿/新生儿结局。
β受体阻滞剂是孕期青光眼的首选治疗药物，但必要时不应排除多药联合治疗。
